Results 41 to 50 of about 3,981,458 (213)
Background Combination of oncolytic vaccinia virus therapy with conventional chemotherapy has shown promise for tumor therapy. However, side effects of chemotherapy including thrombocytopenia, still remain problematic.
Sturm Julia B +11 more
doaj +1 more source
Background: To observe clinical effects of Shen Cao granules on thrombocytopenia in patients with gastrointestinal cancer undergoing chemotherapy. Patients and Methods: Patients under a FOLFIRI chemotherapy regimen (n = 92) were randomly divided into ...
Chunfeng Yu MS +4 more
doaj +1 more source
Bilateral Spontaneous Hemotympanum Secondary to Chemotherapy-Induced Thrombocytopenia
Objective To present a case of spontaneous, bilateral hemotympanum secondary to chemotherapy-induced thrombocytopenia. Methods Case report and review of the literature. Results Bilateral spontaneous hemotympanum is an exceedingly rare event.
Wong, Peter +3 more
openaire +2 more sources
Optimal management of chemotherapy-induced thrombocytopenia with thrombopoietin receptor agonists. [PDF]
Chemotherapy-induced thrombocytopenia (CIT) is a common complication of antineoplastic therapy, resulting in antineoplastic therapy dose reductions, treatment delays, treatment discontinuation, and morbid bleeding events. Despite several decades of research into thrombopoietic growth factors in CIT, there are presently no available U.S.
Al-Samkari H.
europepmc +3 more sources
BackgroundIn patients with cardiovascular (CV) comorbidities that necessitate antiplatelet therapy (APT), its optimal management during chemotherapy-induced thrombocytopenia remains elusive, as the risk of bleeding has to be balanced against the risk of ...
Nina Rosa Neuendorff +13 more
doaj +1 more source
AbstractChemotherapy‐induced thrombocytopenia (CIT) is a common complication of cancer treatment. Evidence has emerged supporting use of romiplostim to treat CIT but predicting clinical response to romiplostim is not possible. To determine utility of endogenous thrombopoietin (TPO) as a biomarker of romiplostim response, we performed an observational ...
Andrew B. Song +4 more
openaire +2 more sources
ANTICOAGULANT-ASSOCIATED PSEUDOTHROMBOCYTOPENIA: A CASE REPORT
Introduction: Anticoagulant-dependent pseudothrombocytopenia (PTDA) is characterized by an in vitro reduction in platelet count due to platelet aggregation in blood samples collected with anticoagulants, such as EDTA, where aggregates are erroneously ...
ADES Cucinelli, B Giorno, JBM Oliveira
doaj +1 more source
Identifying Patterns of Hospitalizations Among Childhood Cancer Survivors: A Population‐Based Study
ABSTRACT Background Childhood cancer survivors (CCSs) experience more hospitalizations than the general population. We aimed to identify distinct hospitalization patterns among Queensland CCSs and the associated characteristics. Methods Cases (aged ≤14 years) diagnosed between 1995 and 2019 while residents of Queensland were identified through the ...
Hai Pham +7 more
wiley +1 more source
Objective: Romiplostim is used to treat chemotherapy-induced thrombocytopenia in a variety of tumor types; however, few studies have examined its use in breast and gynecologic cancers.
Sara Moufarrij +6 more
doaj +1 more source
ABSTRACT Background Therapeutic apheresis (TA) is an established treatment modality for hematologic, neurologic, and immunologic disorders, yet access remains severely limited in sub‐Saharan Africa. Donor apheresis, including platelet apheresis collection from healthy donors, represents an important complementary modality supporting blood product ...
Nosa Bazuaye +33 more
wiley +1 more source

